BRIEF published on 05/12/2025 at 07:35, 1 year 6 months ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year 6 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce des données finales prometteuses pour son essai de Phase 1b évaluant MaaT033 dans la Sclérose Latérale Amyotrophique (SLA). Résultats encourageants et implications thérapeutiques importantes Microbiome Ecosystem Therapies MaaT Pharma Sclérose Latérale Amyotrophique Phase 1b Modulation Du Microbiote
BRIEF published on 04/08/2025 at 07:35, 1 year 7 months ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
BRIEF published on 04/08/2025 at 07:35, 1 year 7 months ago MaaT Pharma annonce des résultats intermédiaires positifs concernant l'innocuité du MaaT033 MaaT Pharma Essai De Phase 2b MaaT033 Allo-GCSH Sécurité DSM
PRESS RELEASE published on 04/08/2025 at 07:30, 1 year 7 months ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
PRESS RELEASE published on 04/08/2025 at 07:30, 1 year 7 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce résultat positif analyse intermédiaire sécurité essai clinique Phase 2b MaaT033 allo-GCSH. DSMB recommande poursuite essai sans modification Sécurité DSMB MaaT Pharma Analyse Intermédiaire Allo-GCSH
BRIEF published on 04/07/2025 at 07:35, 1 year 7 months ago MaaT Pharma : Nouvelle couverture par H.C. Wainwright & Co Cancer Cotation Euronext Microbiome Ecosystem Therapies MaaT Pharma H.C. Wainwright & Co
BRIEF published on 04/07/2025 at 07:35, 1 year 7 months ago MaaT Pharma: New cover by HC Wainwright & Co Cancer Euronext Listing Microbiome Ecosystem Therapies MaaT Pharma HC Wainwright & Co
PRESS RELEASE published on 04/07/2025 at 07:30, 1 year 7 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce l'initiation de la couverture de son titre par H.C. Wainwright & Co, une banque d'investissement américaine, renforçant sa présence sur le marché américain Oncologie Couverture MaaT Pharma Biotechnologies H.C. Wainwright & Co
BRIEF published on 03/27/2025 at 07:35, 1 year 7 months ago MaaT Pharma annonce une augmentation de capital de 13 millions d'euros et des résultats annuels 2024 Résultats Financiers Biotechnologie Augmentation De Capital MaaT013 AGvH
Published on 11/14/2026 at 12:56, 23 hours 41 minutes ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 1 day 11 hours ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 1 day 11 hours ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 1 day 12 hours ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 1 day 12 hours ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 1 day 13 hours ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 1 day 14 hours ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 1 day 17 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 1 day 17 hours ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 2 days 1 hour ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 2 days 1 hour ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 2 days 4 hours ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 2 days 13 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
